Walvax BioTech (SHE:300142) — Stock Price

CN¥13.13 CNY
▼ -0.08% today

Walvax BioTech (SHE:300142) is currently trading at CN¥13.13 CNY, down 0.08% today. Over the past 52 weeks, shares have ranged between CN¥10.91 and CN¥16.00. This page tracks Walvax BioTech's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 300142 company net worth.

Walvax BioTech (300142) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Walvax BioTech's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.

Walvax BioTech Income Statement — Revenue, Profit & Earnings by Year

Walvax BioTech's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue CN¥2.41 Billion CN¥2.82 Billion CN¥4.11 Billion CN¥5.09 Billion CN¥3.46 Billion
Cost of Revenue CN¥750.78 Million CN¥740.48 Million CN¥749.39 Million CN¥673.14 Million CN¥403.54 Million
Gross Profit CN¥1.66 Billion CN¥2.08 Billion CN¥3.36 Billion CN¥4.41 Billion CN¥3.06 Billion
Research & Development CN¥224.19 Million CN¥599.78 Million CN¥776.43 Million CN¥932.89 Million CN¥621.49 Million
SG&A CN¥1.01 Billion CN¥415.85 Million CN¥283.36 Million CN¥260.57 Million CN¥284.44 Million
Total Operating Expenses CN¥1.59 Billion CN¥1.98 Billion CN¥2.75 Billion CN¥3.31 Billion CN¥2.35 Billion
Operating Income CN¥69.96 Million CN¥96.67 Million CN¥613.97 Million CN¥1.10 Billion CN¥710.28 Million
EBITDA CN¥481.71 Million CN¥387.61 Million CN¥1.12 Billion CN¥1.42 Billion CN¥927.65 Million
EBIT CN¥69.96 Million CN¥24.01 Million CN¥831.05 Million CN¥1.17 Billion CN¥792.22 Million
Interest Expense CN¥2.22 Million CN¥8.75 Million CN¥3.81 Million CN¥7.86 Million CN¥6.47 Million
Income Before Tax CN¥166.11 Million CN¥184.50 Million CN¥598.98 Million CN¥1.07 Billion CN¥708.95 Million
Income Tax Expense CN¥40.96 Million CN¥10.10 Million CN¥87.65 Million CN¥132.24 Million CN¥107.59 Million
Net Income CN¥177.74 Million CN¥142.16 Million CN¥419.39 Million CN¥728.65 Million CN¥427.75 Million

Walvax BioTech Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Walvax BioTech's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets CN¥12.07 Billion CN¥14.72 Billion CN¥15.59 Billion CN¥15.34 Billion CN¥13.67 Billion
Total Current Assets CN¥4.55 Billion CN¥7.07 Billion CN¥8.73 Billion CN¥8.95 Billion CN¥7.68 Billion
Cash & Equivalents — — — — —
Short-term Investments — — — CN¥-38.16 Million CN¥-45.05 Million
Net Receivables CN¥2.29 Billion CN¥2.49 Billion CN¥3.26 Billion CN¥3.96 Billion CN¥3.24 Billion
Inventory CN¥574.16 Million CN¥752.59 Million CN¥1.03 Billion CN¥995.81 Million CN¥873.59 Million
Property, Plant & Equipment — — — CN¥3.16 Billion CN¥2.60 Billion
Goodwill CN¥33.66 Million CN¥33.66 Million CN¥33.66 Million CN¥33.66 Million CN¥33.66 Million
Total Liabilities CN¥2.26 Billion CN¥3.22 Billion CN¥4.19 Billion CN¥4.35 Billion CN¥3.68 Billion
Total Current Liabilities CN¥1.94 Billion CN¥2.37 Billion CN¥3.20 Billion CN¥3.51 Billion CN¥3.24 Billion
Long-term Debt CN¥189.56 Million CN¥433.34 Million CN¥434.90 Million CN¥314.24 Million —
Net Debt CN¥-925.29 Million CN¥-3.32 Billion CN¥-3.59 Billion CN¥-3.43 Billion CN¥-3.13 Billion
Total Stockholder Equity CN¥8.62 Billion CN¥9.43 Billion CN¥9.35 Billion CN¥9.08 Billion CN¥8.48 Billion
Retained Earnings CN¥2.86 Billion CN¥3.03 Billion CN¥2.90 Billion CN¥2.50 Billion CN¥1.81 Billion

Walvax BioTech Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Walvax BioTech generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow CN¥494.37 Million CN¥1.04 Billion CN¥1.13 Billion CN¥1.20 Billion CN¥705.28 Million
Capital Expenditures CN¥509.54 Million CN¥550.03 Million CN¥945.52 Million CN¥1.09 Billion CN¥1.10 Billion
Free Cash Flow CN¥-15.17 Million CN¥486.49 Million CN¥188.25 Million CN¥110.31 Million CN¥-398.21 Million
Investing Cash Flow CN¥-2.01 Billion CN¥-1.27 Billion CN¥-810.28 Million CN¥-935.19 Million CN¥-977.15 Million
Financing Cash Flow CN¥-894.58 Million CN¥-371.03 Million CN¥236.64 Million CN¥94.82 Million CN¥1.74 Billion
Dividends Paid CN¥28.99 Million CN¥40.94 Million CN¥15.99 Million CN¥50.11 Million CN¥78.31 Million
Stock-Based Compensation — — — CN¥-38.79 Million CN¥84.75 Million
Depreciation CN¥411.75 Million CN¥388.54 Million CN¥317.23 Million CN¥275.50 Million CN¥143.84 Million
Change in Cash CN¥-2.41 Billion CN¥-595.76 Million CN¥564.69 Million CN¥365.19 Million CN¥1.46 Billion

Walvax BioTech Earnings History — EPS Actual vs. Analyst Estimates

Track Walvax BioTech's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Apr 27, 2026 0.07 0.02 +250.00%
Mar 28, 2026 0.01 — —
Oct 29, 2025 0.07 0.07 +0.00%
Aug 25, 2025 0.03 0.11 -72.73%
Apr 11, 2025 -0.07 -0.06 -16.67%
Dec 31, 2024 -0.07 -0.06 -16.67%
Oct 25, 2024 0.05 0.06 -16.67%
Aug 27, 2024 0.10 0.25 -60.00%